Roche presents positive Phase III results for Tecentriq ® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
Roche today presented positive results from the Phase III IMvigor130 study evaluating Tecentriq ® (atezolizumab) plus platinum-based chemotherapy versus chemotherapy alone for the first-line (initial) treatment of people with previously untreated locally advanced or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Pharmaceuticals | Study